Novartis AG Research and Development Expenses 2010-2024 | NVS

Novartis AG annual/quarterly research and development expenses history and growth rate from 2010 to 2024. Research and development expenses can be defined as an expense arising from studies and product development processes.
  • Novartis AG research and development expenses for the quarter ending September 30, 2024 were $2.392B, a 39.06% decline year-over-year.
  • Novartis AG research and development expenses for the twelve months ending September 30, 2024 were $9.747B, a 8.19% decline year-over-year.
  • Novartis AG annual research and development expenses for 2023 were $11.371B, a 23.98% increase from 2022.
  • Novartis AG annual research and development expenses for 2022 were $9.172B, a 3.86% decline from 2021.
  • Novartis AG annual research and development expenses for 2021 were $9.54B, a 6.24% increase from 2020.
Novartis AG Annual Research and Development Expenses
(Millions of US $)
2023 $11,371
2022 $9,172
2021 $9,540
2020 $8,980
2019 $9,402
2018 $8,489
2017 $8,972
2016 $9,039
2015 $8,935
2014 $9,086
2013 $9,071
2012 $8,588
2011 $9,583
2010 $9,070
2009 $7,469
Novartis AG Quarterly Research and Development Expenses
(Millions of US $)
2024-09-30 $2,392
2024-06-30 $2,367
2024-03-31 $2,421
2023-12-31 $2,567
2023-09-30 $3,925
2023-06-30 $2,304
2023-03-31 $2,575
2022-12-31 $1,812
2022-09-30 $2,542
2022-06-30 $2,498
2022-03-31 $2,320
2021-12-31 $2,409
2021-09-30 $2,380
2021-06-30 $2,400
2021-03-31 $2,351
2020-12-31 $2,333
2020-09-30 $2,146
2020-06-30 $2,441
2020-03-31 $2,060
2019-12-31 $2,853
2019-09-30 $2,199
2019-06-30 $2,051
2019-03-31 $2,299
2018-12-31 $2,234
2018-09-30 $2,147
2018-06-30 $2,126
2018-03-31 $1,982
2017-12-31 $2,502
2017-09-30 $2,239
2017-06-30 $2,062
2017-03-31 $2,169
2016-12-31 $2,584
2016-09-30 $2,224
2016-06-30 $2,190
2016-03-31 $2,041
2015-12-31 $2,472
2015-09-30 $2,190
2015-06-30 $2,206
2015-03-31 $2,067
2014-12-31 $2,537
2014-09-30 $2,161
2014-06-30 $2,178
2014-03-31 $2,210
2013-12-31 $2,311
2013-09-30 $2,216
2013-06-30 $2,247
2013-03-31 $2,297
2012-12-31 $1,877
2012-09-30 $2,191
2012-06-30 $2,285
2012-03-31 $2,235
2011-12-31 $2,523
2011-09-30 $2,475
2011-06-30 $2,397
2011-03-31 $2,188
2010-12-31 $2,592
2010-09-30 $2,548
2010-06-30 $1,893
2010-03-31 $2,037
2009-12-31 $2,148
2009-09-30 $1,825
2009-06-30 $1,802
2009-03-31 $1,694
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $214.456B $45.440B
Novartis has one of the strongest and broadest portfolio of oncology drugs and generics. It continues to build depth in 5 core therapeutic areas Cardio-Renal, Immunology, Neuroscience, Oncology and Hematology, strength in technology platforms - Targeted Protein Degradation, Cell Therapy, Gene Therapy, Radioligand Therapy, and xRNA. Novartis efforts to strengthen its wide and deep oncology portfolio by developing breakthrough treatments. Cosentyx, Entresto, Kesimpta, Zolgensma, Kisqali and Leqvio. In March 2015, Novartis acquired certain oncology products and pipeline compounds from Glaxo. In exchange, it sold its non-influenza Vaccines business to Glaxo. Also, the company has spun off the Alcon business into a separate company. In January 2015, Novartis divested its Animal Health division to Lilly. In July 2015, the company divested its influenza vaccines business to CSL Limited. Novartis has also acquired The Medicines Company, adding Leqvio, to its portfolio. Novartis sold its investment in Roche.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $777.357B 80.52
Novo Nordisk (NVO) Denmark $480.435B 34.65
Johnson & Johnson (JNJ) United States $367.500B 14.91
AbbVie (ABBV) United States $302.340B 15.91
Merck (MRK) United States $249.371B 16.57
AstraZeneca (AZN) United Kingdom $202.127B 17.20
Pfizer (PFE) United States $148.418B 10.15
Sanofi (SNY) $127.247B 11.53
Innoviva (INVA) United States $1.271B 10.58